377 related articles for article (PubMed ID: 30988082)
21. Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.
Liu SV; Frohn C; Minasi L; Fernamberg K; Klink AJ; Gajra A; Savill KMZ; Jonna S
Lung Cancer; 2024 Feb; 188():107469. PubMed ID: 38219288
[TBL] [Abstract][Full Text] [Related]
22. CD74-NRG1 fusions in lung adenocarcinoma.
Fernandez-Cuesta L; Plenker D; Osada H; Sun R; Menon R; Leenders F; Ortiz-Cuaran S; Peifer M; Bos M; Daßler J; Malchers F; Schöttle J; Vogel W; Dahmen I; Koker M; Ullrich RT; Wright GM; Russell PA; Wainer Z; Solomon B; Brambilla E; Nagy-Mignotte H; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Altmüller J; Becker C; Nürnberg P; Heuckmann JM; Stoelben E; Petersen I; Clement JH; Sänger J; Muscarella LA; la Torre A; Fazio VM; Lahortiga I; Perera T; Ogata S; Parade M; Brehmer D; Vingron M; Heukamp LC; Buettner R; Zander T; Wolf J; Perner S; Ansén S; Haas SA; Yatabe Y; Thomas RK
Cancer Discov; 2014 Apr; 4(4):415-22. PubMed ID: 24469108
[TBL] [Abstract][Full Text] [Related]
23. The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer.
Umemoto K; Sunakawa Y
Crit Rev Oncol Hematol; 2021 Oct; 166():103465. PubMed ID: 34454058
[TBL] [Abstract][Full Text] [Related]
24.
Heining C; Horak P; Uhrig S; Codo PL; Klink B; Hutter B; Fröhlich M; Bonekamp D; Richter D; Steiger K; Penzel R; Endris V; Ehrenberg KR; Frank S; Kleinheinz K; Toprak UH; Schlesner M; Mandal R; Schulz L; Lambertz H; Fetscher S; Bitzer M; Malek NP; Horger M; Giese NA; Strobel O; Hackert T; Springfeld C; Feuerbach L; Bergmann F; Schröck E; von Kalle C; Weichert W; Scholl C; Ball CR; Stenzinger A; Brors B; Fröhling S; Glimm H
Cancer Discov; 2018 Sep; 8(9):1087-1095. PubMed ID: 29802158
[TBL] [Abstract][Full Text] [Related]
25. NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis.
Nagasaka M; Ou SI
Trends Cancer; 2022 Mar; 8(3):242-258. PubMed ID: 34996744
[TBL] [Abstract][Full Text] [Related]
26. Plain language summary of publication: new information for the potential role of afatinib in treating people with
Cadranel J
Future Oncol; 2022 Jun; 18(18):2193-2200. PubMed ID: 35400204
[TBL] [Abstract][Full Text] [Related]
27. CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization.
Werr L; Plenker D; Dammert MA; Lorenz C; Brägelmann J; Tumbrink HL; Klein S; Schmitt A; Büttner R; Persigehl T; Shokat KM; Wunderlich FT; Schram AM; Peifer M; Sos ML; Reinhardt HC; Thomas RK
Mol Cancer Ther; 2022 May; 21(5):821-830. PubMed ID: 35247925
[TBL] [Abstract][Full Text] [Related]
28. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring
Kim DW; Schram AM; Hollebecque A; Nishino K; Macarulla T; Rha SY; Duruisseaux M; Liu SV; Al Hallak MN; Umemoto K; Wesseler C; Cleary JM; Springfeld C; Neuzillet C; Joe A; Jauhari S; Ford J; Goto K
Future Oncol; 2024 Feb; ():. PubMed ID: 38348690
[TBL] [Abstract][Full Text] [Related]
29. Fluorescent in situ hybridization has limitations in screening NRG1 gene rearrangements.
Zhang X; Li L; Gao F; Liu B; Li J; Ren S; Peng S; Qiu W; Pu X; Ye Q
Diagn Pathol; 2024 Jan; 19(1):1. PubMed ID: 38173003
[TBL] [Abstract][Full Text] [Related]
30. Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.
Odintsov I; Mattar MS; Lui AJW; Offin M; Kurzatkowski C; Delasos L; Khodos I; Asher M; Daly RM; Rekhtman N; de Stanchina E; Ganji G; Ladanyi M; Somwar R
J Thorac Oncol; 2021 Jul; 16(7):1149-1165. PubMed ID: 33839363
[TBL] [Abstract][Full Text] [Related]
31. Successful targeting of the
Wu X; Zhang D; Shi M; Wang F; Li Y; Lin Q
Ann Transl Med; 2021 Oct; 9(19):1507. PubMed ID: 34805369
[TBL] [Abstract][Full Text] [Related]
32. Fusion genes in pancreatic tumors.
Gkountakos A; Singhi AD; Westphalen CB; Scarpa A; Luchini C
Trends Cancer; 2024 May; 10(5):430-443. PubMed ID: 38378317
[TBL] [Abstract][Full Text] [Related]
33. Distribution of NRG1 Gene Fusions in a Large Population of Chinese Patients with NSCLC.
Ke H; Shen W; Hu A; Ou Q; Lu S
J Thorac Oncol; 2019 Dec; 14(12):e263-e266. PubMed ID: 31757375
[No Abstract] [Full Text] [Related]
34. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
[TBL] [Abstract][Full Text] [Related]
35. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
Takeuchi K; Choi YL; Soda M; Inamura K; Togashi Y; Hatano S; Enomoto M; Takada S; Yamashita Y; Satoh Y; Okumura S; Nakagawa K; Ishikawa Y; Mano H
Clin Cancer Res; 2008 Oct; 14(20):6618-24. PubMed ID: 18927303
[TBL] [Abstract][Full Text] [Related]
36. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer.
Pfarr N; Stenzinger A; Penzel R; Warth A; Dienemann H; Schirmacher P; Weichert W; Endris V
Genes Chromosomes Cancer; 2016 Jan; 55(1):30-44. PubMed ID: 26394895
[TBL] [Abstract][Full Text] [Related]
37. Neuregulin 1 Gene (
Rosas D; Raez LE; Russo A; Rolfo C
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680187
[TBL] [Abstract][Full Text] [Related]
38. Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.
Seker-Cin H; Tay TKY; Kazdal D; Kluck K; Ball M; Neumann O; Winter H; Herth F; Heußel CP; Savai R; Schirmacher P; Thomas M; Budczies J; Allgäuer M; Christopoulos P; Stenzinger A; Volckmar AL
Lung Cancer; 2023 Oct; 184():107317. PubMed ID: 37586177
[TBL] [Abstract][Full Text] [Related]
39. Clinical Utility of Cell-Free DNA for the Detection of
McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
[No Abstract] [Full Text] [Related]
40. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.
Zhu VW; Klempner SJ; Ou SI
Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]